FDA approves Octapharma’s Octagam® 10% for adult dermatomyositis
Bioengineer
JULY 20, 2021
FDA approval based on positive results of international, multi-center ProDERM study. “The FDA approval of Octagam® 10% as a safe and effective treatment for dermatomyositis in adults is exciting news for patients who previously relied on unapproved treatments,” said Octapharma USA President Flemming Nielsen.
Let's personalize your content